US Stock Market Closed

Dashboard

Aclaris Therapeutics, Inc. (ACRS)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

CEO

Neal S. Walker

Employees

77

Industry

Immunology Biopharmaceuticals

Sector

Healthcare

Headquarters

Malvern

Exchange

NASDAQ

Summary Stats

Market Cap

871M

Revenue

6.14M

Net Income

-83.3M

EPS

-$1.33

Price-to-Earnings

-9.83

Price-to-Book

3.7

Debt-to-Equity

0.18

News

Analyst Ratings

Price targets projected by 3 analysts

High

$5.00

Average

$4.83

Low

$4.00

Ratings calculated by 4 analysts

Buy

4

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q2 2022

Last Earnings

Above by $0.05

Actual

-$0.31 +13.9%

Consensus

-0.36

Report Date

Year Ago

-0.34

Year Ago Change %

Up 8%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites